bbo-11818
Generic: KRAS Mutant Inhibitor BBO-11818·Code: BBO-11818
bbo-11818: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | Phase 1 |
Clinical Trials (1)
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers
Frequently asked questions
Who is developing bbo-11818?
bbo-11818 is being developed by BridgeBio Oncology Therapeutics, Inc..
How many clinical trials involve bbo-11818?
BioSniper tracks 1 clinical trial involving bbo-11818.
Get deeper analysis on bbo-11818
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis